News | October 23, 2014

One-year Outcomes Good for Superficial Femoral Artery Stent

October 23, 2014 — The use of stents has improved management and outcomes of coronary artery disease, and clinical trials are attempting to prove the same will be true for superficial femoral artery disease. Randomized trials have shown favorable results for self-expanding nitinol stents compared with balloon angioplasty. A new report seeks to test this treatment in a real-world population of patients enrolled in an observational registry.

The Journal of Endovascular Therapy offers a prospective multicenter observational study of patients with symptomatic superficial femoral artery stenosis. A total of 998 patients suffering from chronic limb ischemia were enrolled at 13 German medical centers. Twelve-month outcomes of the participants were assessed.

The median lesion length was 8 cm, but there was no restriction on the length of lesion to be treated. The authors cite this criterion as supporting the real-world aspect of the study population. Rather than including primarily high-risk patients, a general mix of patients participated in the study. However, a third of the patients had diabetes, and 43 percent were current smokers.

In all, 1,050 lesions were treated. Twelve months after surgery, target lesion revascularization — the primary endpoint of the study — was achieved in 136, or 17 percent, of the patients. Restenosis occurred in 24 percent of the patients and reocclusion in 10 percent. These results indicate that stent use is safe and is delivering favorable outcomes at the one-year mark.

A commentary in the same issue asserts that the “real-world” study group is actually representative of a narrower set of patients, largely because the median lesion length was less than 10 cm—a length that has previously shown good success with intervention. The author notes that, although the study validates that superficial femoral artery stenting is producing satisfactory patency results, patient quality of life and functionality measures might better represent success.

For more information: www.jeytonline.org

Related Content

MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Overlay Init